Literature DB >> 2060878

Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.

J E McDonagh1, V V Nathan, I C Bonavia, G R Moyle, A R Tanner.   

Abstract

The clinical value and sensitivity of serum caffeine clearance measurement has been evaluated as an indicator of hepatic disease. After a 17 hour caffeine exclusion period, 300 mg of caffeine citrate was administered orally to the study subjects. Serum samples were taken four and 16 hours later. Serum caffeine concentrations were measured using an enzyme multiplied immunoassay technique (EMIT) and a clearance value derived. Conventional liver function tests were measured at the same time. A total of 103 subjects attending the medical unit in a district general hospital were studied. Twenty one had alcoholic liver disease, 11 non-alcoholic cirrhosis, nine non-cirrhotic liver disease, 21 suspected liver disease, six hepatic tumours, and 35 were hospital and normal control subjects. Caffeine clearance values were lowest in subjects with alcoholic liver disease (median 0.19 ml/min/kg, range 0.04-0.61 ml/min/kg) and significantly reduced in all subjects with liver disease (median 0.32 ml/min/kg, range 0.04-2.68 ml/min/kg) compared with control subjects (median 1.27 ml/min/kg, p less than 0.001). In subjects with suspected liver disease subsequently shown to have another explanation for abnormal liver function test results, caffeine clearance values were normal (median 1.31 ml/min/kg, range 0.23-2.64 ml/min/kg) and significantly different, p less than 0.001, from those of subjects with liver disease. Serum albumen values were not different for these latter two groups. Using a cut off value of 0.86 ml/min/kg, caffeine clearance measurement was 100% sensitive for alcoholic liver disease and 89% sensitive for all liver disease. The respective sensitivities for conventional liver function test measurement were 76% and 83%. In the suspected liver disease group, caffeine clearance was abnormal in only 24%, conventional liver function tests were abnormal in 95%. The respective specificities for caffeine clearance and liver function test measurement in control subjects were 93% and 100%. Caffeine clearance determined by EMIT is a simple inexpensive hepatic metabolic function test. This study indicates that it is a more sensitive indicator of structural liver disease than conventional liver function tests, especially for alcoholic liver disease. The test could be widely introduced as a useful, repeatable assessment of hepatic function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060878      PMCID: PMC1378889          DOI: 10.1136/gut.32.6.681

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Use of quantitative liver function tests--caffeine clearance and galactose elimination capacity--after orthotopic liver transplantation.

Authors:  R A Nagel; L Y Dirix; K M Hayllar; R Preisig; J M Tredger; R Williams
Journal:  J Hepatol       Date:  1990-03       Impact factor: 25.083

2.  Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis.

Authors:  R Joeres; H Klinker; H Heusler; J Epping; W Zilly; E Richter
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

3.  Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night.

Authors:  A Wahlländer; S Mohr; G Paumgartner
Journal:  J Hepatol       Date:  1990-03       Impact factor: 25.083

4.  Caffeine: a model compound for measuring liver function.

Authors:  E Renner; H Wietholtz; P Huguenin; M J Arnaud; R Preisig
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

5.  Impaired elimination of caffeine in cirrhosis.

Authors:  P V Desmond; R V Patwardhan; R F Johnson; S Schenker
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

6.  Factors influencing survival at one year in patients with nonbiliary hepatic parenchymal cirrhosis.

Authors:  M Adler; J Van Laethem; A Glibert; M Gelin; N Bourgeois; P Vereerstraeten; M Cremer
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

7.  Overnight salivary caffeine clearance: a liver function test suitable for routine use.

Authors:  G Jost; A Wahlländer; U von Mandach; R Preisig
Journal:  Hepatology       Date:  1987 Mar-Apr       Impact factor: 17.425

8.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

9.  Decreased systemic clearance of caffeine due to cimetidine.

Authors:  L J Broughton; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

10.  Evaluation of caffeine plasma levels by an automated enzyme immunoassay (EMIT) in comparison with a high-performance liquid chromatographic method.

Authors:  T Zysset; A Wahlländer; R Preisig
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

  10 in total
  5 in total

1.  The role of salivary caffeine clearance in the diagnosis of chronic liver disease.

Authors:  Anurag Tripathi; Brijesh Tiwari; Ranjit Patil; Vikram Khanna; Vandana Singh
Journal:  J Oral Biol Craniofac Res       Date:  2015-01-23

2.  Caffeine clearance in the horse.

Authors:  J Schumacher; J S Spano; R C Wilson; F J DeGraves; S H Duran; D C Ruffin
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

Review 3.  Caffeine citrate: a review of its use in apnoea of prematurity.

Authors:  A M Comer; C M Perry; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

Review 4.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

5.  Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study.

Authors:  Giovanni Tarantino; Domenico Capone; Paola Contaldi; Adriana Gianno; Mosca Teresa; Antonella Tufano
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.